University of California, Los Angeles
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of California, Los Angeles
Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
A $70m fund will back prior investments, while a $430m fund will launch new biotech firms. Harper and Seidenberg tapped into their Amgen connections for the CEO who helms new company Acelyrin.
- Academic and Research Institutions